Welcome to GLIOTRAIN

Exploiting GLIOblastoma intractability to address European research TRAINing needs in translational brain tumour research, cancer systems medicine and integrative multi-omics

A MARIE SKŁODOWSKA-CURIE ACTIONS (MSCA) Innovative Training Network (ITN)

About GLIOTRAIN

An estimated 240,000 cases of brain and nervous system tumours are diagnosed every year, worldwide and Glioblastoma (GBM) is the most frequent and aggressive brain tumour. New treatment options and effective precision medicine therapies are urgently required. GLIOTRAIN is a multi-sectoral industry-academia collaboration, funded by the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie ITN initiative, that will work to identify novel strategies to treat GBM as well as investigating resistance mechanisms in this devastating disease.

Latest news

GLIOTRAIN consortium member, the Luxembourg Institute of Health (LIH), establishes a collection of preclinical patient-derived brain tumour models to accelerate drug development

Dr Anna Golebiewska and Prof Simone Niclou and GLIOTRAIN ESR Yahaya Yabo from the NORLUX Neuro-Oncology Laboratory at the LIH Department of Oncology (DONC), along with key collaborators, have established a large collection of patient-derived glioma organoids and xenograft models that mimic the specific features of patient brain tumours. The work was undertaken in collaboration with the Centre Hospitalier de Luxembourg (CHL), the Laboratoire National de Santé (LNS), the Luxembourg Centre for System

Members of the GLIOTRAIN Consortium publish GBM state of the art position paper

Several members of the GLIOTRAIN consortium along with key collaborators Prof Roel Verhaak (The Jackson Laboratory , Farmington, CT, USA), Mr David O’Brien and Mr James Clerkin (National Neurosurgical Department, Beaumont Hospital, Dublin, Ireland) have recently published (September 2020) a state of the art position paper discussing novel treatment approaches and ongoing trials in the IDH-wildtype glioblastoma (GBM) setting.

Third GLIOTRAIN Annual meeting takes place “virtually” in September 2020

In September 2020 the 3rd GLIOTRAIN annual meeting took place. This year the meeting was held virtually. All Beneficiaries were represented with all early stage researchers (ESRs) and many PIs in attendance. The meeting this year focussed on the mitigation measures being implemented centrally to ensure that ESRs will receive the full network-wide training programme despite the current COVID-19 pandemic. This will be done for the most part by moving training online.

The Team